Bolt Biotherapeutics, Inc. Stock Price, News & Analysis

Bolt Biotherapeutics (BOLT) reported third-quarter 2022 results, highlighting the dose-escalation trials for BDC-1001 targeting HER2-expressing tumors, with recruitment on track for completion by year-end 2022. Collaboration revenue rose to $2.1 million, a 50% increase from the previous quarter. R&D expenses remained stable at $19.0 million, while G&A expenses increased to $5.5 million. The company’s cash balance stands at $209.6 million, expected to fund operations through 2025. Upcoming milestones include topline data from BDC-1001 and the initiation of BDC-3042 clinical studies in 2023.

Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) presented new preclinical data on BDC-3042, a Dectin-2 targeting agonistic antibody, at the 2022 SITC Annual Meeting in Boston. The innovative therapy aims to convert immunosuppressive tumor-associated macrophages into immunostimulatory cells, potentially enhancing anti-tumor immunity. Key findings include BDC-3042's ability to selectively activate these macrophages, thereby facilitating anti-tumor activity in preclinical models. Bolt is advancing BDC-3042 through IND-enabling studies as part of its commitment to developing novel cancer immunotherapies.

Bolt Biotherapeutics (Nasdaq: BOLT) will participate in the Stifel 2022 Healthcare Conference on Nov. 16, 2022, at 1:15 p.m. EST in New York. The event will feature a fireside chat with management, and a live webcast can be accessed on Bolt's website. The company is known for developing innovative immuno-oncology therapeutics, including BDC-1001 and BDC-3042, which target HER2 and modulate myeloid biology, respectively. Archived replays will be available for 30 days post-event.

Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company focusing on immuno-oncology, announced participation in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference.

The event will take place on September 13, 2022, at 12:20 p.m. ET in New York City. A live webcast will be accessible on Bolt's website, with archived replays available for 30 days post-event.

Bolt's pipeline includes innovative therapies targeting cancer, highlighting their commitment to advancing treatment options.

Bolt Biotherapeutics (Nasdaq: BOLT) reported Q2 2022 financial results, highlighting $223.6 million in cash to fund operations through 2025. Clinical progress includes the ongoing BDC-1001 dosage studies, with anticipated data readouts later this year. The company has prioritized its pipeline, ceasing BDC-2034 due to off-target toxicity, while focusing on BDC-1001 and BDC-3042. Collaboration revenue rose to $1.4 million, a 75% increase from Q1 2022. R&D expenses fell slightly to $18.9 million, while G&A expenses rose to $5.5 million.

Bolt Biotherapeutics announces a presentation at the 2022 ASCO Annual Meeting in Chicago, showcasing data on myeloid cell presence in solid tumors, even with low T cell infiltration. The poster, titled "Characterization of tumor antigen expression and myeloid immune profiles to inform the development of immune-stimulating antibody conjugates (ISACs)," highlights myeloid cells' potential as therapeutic targets. The insights could enhance the efficacy of myeloid-targeted therapies, benefiting patients resistant to T cell approaches. The abstract number is 2557, and the poster session is scheduled for June 5.

Bolt Biotherapeutics reported Q1 2022 financial results, showing collaboration revenue of $0.8 million, driven by R&D partnerships. R&D expenses rose to $18.4 million, reflecting progress in clinical trials and IND-enabling activities. General and administrative expenses increased to $6.3 million. The company holds a robust cash balance of $246.8 million, expected to fund operations and key milestones into 2024. The lead program, BDC-1001, is on track for data readouts in H2 2022, with promising early signs of clinical disease control.

Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotech firm, will present an overview at the 21st Annual Needham Healthcare Conference on April 14, 2022, at 12:45 p.m. PT. The presentation will highlight Bolt's innovative immuno-oncology therapeutics that utilize Boltbody™ to target tumors. Key products include BDC-1001, a HER2-targeting agent in a Phase 1/2 trial, and others targeting CEA and Dectin-2. A live webcast will be available on Bolt's website, with archived replays accessible for 30 days post-event.

Bolt Biotherapeutics (BOLT) reported its financial results for Q4 and the full year 2021, showcasing a cash balance of $271.6 million to fund operations through 2024. The company is progressing with BDC-1001, a treatment for HER2-expressing solid tumors, expected to reach Phase 2 dose identification later in 2022. The ongoing combination study with OPDIVO® is advancing well, showing promising stability and partial responses. R&D expenses rose to $75.7 million, reflecting increased clinical trial costs. Total revenue for 2021 was $1.3 million, marking growth from $0.2 million in 2020.